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ack J. Hall, MD,§ Tift Mann, MD, Louis A. Cannon, MD,¶ Mark W. I. Webster,
BCHB,# Gregory J. Mishkel, MD,** Charles D. O’Shaughnessy, MD,††
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onald S. Baim, MD§§
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ndiana; Raleigh, North Carolina; Petoskey, Michigan; Springfield, Illinois; Elyria, Ohio; and
klahoma City, Oklahoma
bjectives The TAXUS ATLAS Small Vessel (SV) and Long Lesion (LL) multicenter studies compared
he performance of the thin-strut (0.0038 inch) TAXUS Liberté 2.25-mm stent (Boston Scientiﬁc;
atick, Massachusetts) and the TAXUS Liberté 38-mm long stent (Boston Scientiﬁc; Natick, Massa-
husetts) with the earlier paclitaxel-eluting TAXUS Express (Boston Scientiﬁc) stent that has identical
olymer, drug dosage, and release kinetics but different stent geometry and thicker struts (0.0052
nch).
ackground The TAXUS Liberté stent was designed with thinner and more even strut spacing to
rovide more uniform drug distribution, as well as increased ﬂexibility and conformability. Clinical
eneﬁts of the new stent design have not been evaluated.
ethods The TAXUS ATLAS SV and LL studies are nonrandomized studies comparing outcomes of
he TAXUS Liberté 2.25 mm (N  261) and TAXUS Liberté 38 mm (N  150) stents to TAXUS Ex-
ress historical control groups derived from the TAXUS IV and V trials. Inclusion/exclusion criteria for
AXUS Express and Liberté groups were similar in both studies.
esults Each study met its primary end point of noninferiority of 9-month in-segment diameter
tenosis. Furthermore, TAXUS Liberté 2.25 mm, when compared with TAXUS Express, signiﬁcantly
educed the rate of both 9-month angiographic restenosis (18.5% vs. 32.7%, p  0.0219) and 12-
onth target lesion revascularization (6.1% vs. 16.9%, p  0.0039). In addition, TAXUS Liberté 38
m signiﬁcantly reduced the risk of 12-month myocardial infarction compared with TAXUS Express
1.4% vs. 6.5%, p  0.0246).
onclusions The thinner-strut TAXUS Liberté stent improved outcomes compared with the earlier
AXUS Express stent in both SVs and LLs (A Study of the TAXUS Liberté Stent for the Treatment of
e Novo Coronary Artery Lesions in Small Vessels; NCT00371748; A Study of the TAXUS Liberté Stent
or the Treatment of Long De Novo Coronary Artery Lesions; NCT00371475). (J Am Coll Cardiol Intv
008;1:699–709) © 2008 by the American College of Cardiology Foundation
rom the *Center for Cardiac & Vascular Research, Washington Adventist Hospital, Takoma Park, Maryland; †Mercy
ngiography Unit, Mercy Hospital, Auckland, New Zealand; ‡Angiographic Core Laboratory, Brigham and Women’s Hospital,
oston, Massachusetts; §The Heart Center, St. Vincent’s Hospital, Indianapolis, Indiana; Wake Heart Associates, Wake Medical
enter, Raleigh, North Carolina; ¶Cardiac & Vascular Research Center, Northern Michigan Hospital, Petoskey, Michigan;
Cardiac Investigations Unit, Auckland City Hospital, Auckland, New Zealand; **Prairie Heart Institute, St. John’s Hospital,
pringfield, Illinois; ††Elyria Memorial Hospital, Elyria, Ohio; ‡‡Oklahoma Foundation for Cardiovascular Research, Oklahoma
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700ompared with bare-metal stents, drug-eluting stents sig-
ificantly reduce the incidence of restenosis and the need for
epeat revascularization in patients with relatively simple
e-novo coronary lesions (1,2). More recently, the safety
nd effectiveness of the first-generation TAXUS (Boston
cientific Corporation, Natick, Massachusetts) and Cypher
Cordis/Johnson and Johnson; Miami Lakes, Florida) drug-
luting stents have been evaluated in the more challenging
ubsets of smaller vessels and longer lesions (3,4). Small
essel (SV) diameter remains a significant predictor of reste-
osis or stent thrombosis after drug-eluting stent implantation
5–7), while long lesions (LL), particularly those requiring
ultiple stents, may be associated with an increased risk of
eriprocedural myocardial infarction (MI) (4).
Stent design is recognized as a determinant of stent
erformance (8). Strut thickness, metal composition, and
adial strength can each influence short- and long-term
utcomes (9,10). The new-generation TAXUS Liberté
stent was developed using the
same proven polymer-based,
paclitaxel-eluting technology as
on TAXUS Express but applied
to the newer Liberté stent. This
new stent design has thinner
struts and more uniform distri-
bution of struts than the earlier
TAXUS Express to improve
deliverability, conformability,
and more homogenous drug dis-
tribution (11). The TAXUS
ATLAS study demonstrated
that in noncomplex lesions
TAXUS Liberté and TAXUS
Express performance was similar
(12). The current report de-
scribes the outcomes of the non-
andomized, historically controlled TAXUS ATLAS SV
nd TAXUS ATLAS LL trials that compared the perfor-
ance of the thin-strut TAXUS Liberté to the TAXUS
xpress in patients with SVs or LLs, respectively.
ethods
evice description. The TAXUS Liberté-SR Stent (Boston
cientific Corporation) consists of a balloon-expandable
iberté stent with a polymer coating containing 1 g/mm2
eart Hospital, Oklahoma City, Oklahoma; and §§Boston Scientific Corporation,
atick, Massachusetts. This study was supported by Boston Scientific Corporation.
rs. Turco and Cannon have received consulting fees/honoraria and have been on the
dvisory board and the Speakers’ Bureau for Boston Scientific Corporation; Dr.
rmiston has received consulting fees/honoraria and has been on the advisory board
or Boston Scientific Corporation; Drs. Popma and Mishkel have received consulting
bbreviations
nd Acronyms
I  confidence interval
S  percent diameter
tenosis
L  long lesion(s)
ACE  major adverse
ardiac events
I  myocardial infarction
LD  minimum lumen
iameter
VD  reference vessel
iameter
V  small vessel(s)
LR  target lesion
evascularizationees/honoraria, have been on the Speakers’ Bureau, and have received research grants
oston Scientific Corporation; Dr. Mann has been on the advisory board for Boston af paclitaxel in a slow-release formulation. Drug dosing and
elease kinetics are identical to that of the TAXUS
xpress-SR Stent (Boston Scientific Corporation). Both
tents are made from 316L stainless steel, but the Liberté
latform has a more uniform strut pattern and thinner struts
0.0038 inches or 0.097 mm) than the Express platform
0.0052 inches or 0.132 mm).
atient selection and procedures. The study protocols were
pproved by local ethics committees, and all patients pro-
ided written informed consent before enrollment. The
AXUS ATLAS SV and LL study designs are summarized
n Table 1. A total of 261 patients were enrolled in the
AXUS ATLAS SV study, and 150 patients were enrolled
n the TAXUS ATLAS LL study. General inclusion and
xclusion criteria were the same as in the TAXUS ATLAS
nd TAXUS IV and V trial protocols and have been
escribed previously (2,4,12). The only difference among
hese protocols was related to target lesion length and target
essel size.
ontrol groups. The historical control groups were derived
rom the TAXUS IV and V trials (2,4). The TAXUS
TLAS SV study results were compared with those seen in
control group of 75 TAXUS V trial patients with reference
essel diameter (RVD) 2.5 mm, lesion length 28 mm,
nd receiving a single TAXUS Express 2.25-mm stent. The
AXUS ATLAS LL study results were compared with
hose seen in a control group of 145 TAXUS IV and V trial
atients with RVD 2.5 and 4.0 mm, lesion length 26
nd 34 mm and receiving 1 TAXUS Express stents.
ultiple stenting was only allowed for bailout purposes in
he TAXUS ATLAS LL study and in the TAXUS IV trial.
lanned multiple stenting was permitted in the TAXUS V
rial. Patient flow through 12-month follow-up is shown in
igure 1.
ual antiplatelet therapy. Loading doses of clopidogrel
300 mg) or ticlopidine (500 mg) and aspirin (300 mg) were
dministered before the procedure. After stent implanta-
ion, clopidogrel (75 mg daily) or ticlopidine (250 mg twice
aily) was mandated for a minimum of 6 months, and
spirin therapy (100 mg daily), mandated for 9 months,
as recommended indefinitely.
uantitative angiographic analysis. Identical angiographic
ethods were used for the TAXUS ATLAS studies and
AXUS IV and V trials. Quantitative coronary angiography
nalysis, performed by the same Core Laboratory, used a
alidated automated edge detection algorithm (Medis
cientific Corporation; Dr. Webster has received research grants Boston Scientific
orporation; Dr. O’Shaughnessy has received consulting fees/honoraria, has been on
he Speakers’ Bureau, has received research grants, and has been on the advisory board
or Boston Scientific Corporation; and Drs. Mandinov, Dawkins, and Baim are
ull-time employees and stockholders of Boston Scientific Corporation.
anuscript received April 25, 2008; revised manuscript received July 25, 2008,
ccepted September 12, 2008.
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701MS, Leiden, the Netherlands). Minimum lumen diameter
MLD) was measured within the stent (in-stent), within the
djacent 5-mm proximal and distal edges of the stent, and
ithin the segment between the proximal and distal refer-
nce vessel (in-segment). Diameter stenosis (DS) was de-
ned as (1 [MLD/RVD]) 100%. Binary restenosis was
efined as a 50% DS.
eﬁnitions. Major adverse cardiac events (MACE) and
tent thromboses were adjudicated by an independent clin-
cal events committee that was similar for all TAXUS
TLAS studies and the TAXUS IV and V trials. The
linical and angiographic end point definitions were iden-
ical to those in the TAXUS ATLAS study and the
AXUS IV and V trials (2,4,12). Stent thrombosis was
djudicated according to both the protocol definition and
he Academic Research Consortium definition (13).
nd points. The primary end point of both the TAXUS
TLAS SV and LL trials was noninferiority of 9-month
n-segment DS versus the historical TAXUS Express con-
rol subjects. Secondary end points in both studies included
uantitative coronary angiography and clinical end points.
tatistical methodology. Baseline, post-procedural, and
ollow-up data were summarized using descriptive statistics
nd presented as proportions (%, count/sample size) or
ean  standard deviation. The student t test was used for
omparing continuous variables. The chi-square or Fisher
xact tests, as appropriate, were used for comparing propor-
ions. The Kaplan-Meier product-limit method and log-
ank test were used to assess time-to-event end points
etween groups.
For noninferiority testing of the primary end point in the
AXUS ATLAS SV study, enrollment of 260 patients con-
Table 1. Study Designs of the TAXUS ATLAS SV and LL Studies
TAX
Study design
Investigative sites 23 sites in North
Time of enrollment February 2005 t
Patients (intent-to-treat) 261
RVD* 2.2 and 2.5 m
Lesion length* 10 and 28 m
Enrollment
Number of target lesions and study stents allowed
Control group (historical patients
with similar inclusion/exclusion criteria)
Includes TAXUS
TAXUS Expres
RVD 2.5 mm
Lesion length
Single study s
Primary end point
Clinical follow-up
*By visual estimation; †Pre-dilation was mandated in the TAXUS IV and V trials; ‡Additional stents a
LL long lesion; RVD reference vessel diameter; SV small vessel.erred 89% power with the following assumptions based on the tAXUS IV and VI trials: a noninferiority margin of 10.0%, a
-month in-segment DS of 37.1%, and 30% attrition.
For noninferiority testing of the primary end point in the
AXUS ATLAS LL study, the required enrollment of 150
ubjects conferred 80% power with the following assumptions
ased on the TAXUS IV trial: a noninferiority margin of 6.9%,
9-month in-segment DS of 29.0%, and 30% attrition.
Primary end points in both studies were adjusted by
ropensity score analysis to control for differing baseline
haracteristics. Propensity score analysis was performed
sing a hierarchical logistic regression model with a stepwise
election process and an entry/exit criterion of 0.10. The per
rotocol population excluded patients who did not receive
he study stent and was the main population of interest for
he primary end point.
Multivariate analysis was used to determine predictors of
-year clinical outcomes. All covariates were modeled by
nivariate and multivariate analysis using a stepwise procedure
n a Cox regression model. The significance level for entry/exit
as set at 0.10. Linear regression and logistic regression
odels were used to determine predictors of continuous and
ategorical angiographic variables, respectively. All outcomes
ere adjusted by propensity score analysis. All baseline vari-
bles considered for both propensity score adjustment and
ultivariate analysis are outlined in Table 2. Stent type was
lso considered for multivariate modeling. Statistical signifi-
ance was accepted at a value of p  0.05.
esults
aseline characteristics in the TAXUS ATLAS SV and LL
rials. Baseline patient and lesion characteristics for both
LAS SV TAXUS ATLAS LL
Prospective, single-arm, historically controlled
ica and Asia Paciﬁc 24 sites in North America and Asia Paciﬁc
h 2006 March 2005 to May 2006
150
2.7 and 4.0 mm
26 and 34 mm
After successful pre-dilation†
One target lesion and single study stent‡
nts with:
mm
m
Includes TAXUS IV and V patients with:
TAXUS Express stent
RVD 2.5 mm and 4.0 mm
Lesion length 26 mm and 34 mm
Single or planned multiple study stents§
9-month % diameter stenosis (in-segment)
1, 4, and 9 months and 1, 2, 3, 4, and 5 years
for bailout purposes only; §Planned multiple stenting allowed in the TAXUS V trial only.US AT
Amer
o Marc
m
m
V patie
s 2.25
28 m
tent
llowedhe TAXUS ATLAS SV and LL studies are shown in
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702able 2. In the TAXUS ATLAS SV study, baseline
haracteristics were well matched between the groups;
owever, the target lesion was significantly longer in the
ontrol patients. In the TAXUS ATLAS LL study,
AXUS Liberté patients were more likely to have stable
ather than unstable angina, hyperlipidemia, longer lesions,
alcification, and American College of Cardiology/
merican Heart Association type B2 or C lesions but were
ess likely to have thrombus than the control patients.
rocedural characteristics in the TAXUS ATLAS SV and LL
rials. In both studies, procedure time in patients without a
ontarget lesion treated was significantly shorter for
AXUS Liberté than TAXUS Express (Table 2). Technical
uccess, defined as stent delivery with no device malfunc-
ion, was identical for the 2 stents: 97.3% in the TAXUS
TLAS SV study and 100.0% in the TAXUS ATLAS LL
tudy. Clinical success was similar for both stents in the
Figure 1. The TAXUS ATLAS Small Vessel and Long Lesion Study Flow
Study ﬂow and follow-up for the TAXUS ATLAS Small Vessel (A) and TAXUS AT
to the per protocol population, consisting only of patients who received a stuAXUS ATLAS SV study but significantly higher for 2he TAXUS Liberté in the TAXUS ATLAS LL study
Table 2). In both studies, stented length was significantly
onger for TAXUS Liberté than TAXUS Express, although
he stent-to-lesion length ratio was lower for TAXUS
iberté. The frequency of multiple stenting was similar in
he TAXUS ATLAS SV study but higher for the TAXUS
xpress in the TAXUS ATLAS LL study reflecting the
ack of a 38-mm length for the TAXUS Express.
rimary end point in the TAXUS ATLAS SV and LL trials.
he primary noninferiority end point was met in both the
AXUS ATLAS SV and LL studies (Fig. 2). In both
tudies, the upper 1-sided 95% confidence interval (CI) of
he difference in in-segment DS between groups was sig-
ificantly less than the pre-specified margin, thus demon-
trating the noninferiority of the TAXUS Liberté 2.25 mm
nd the TAXUS Liberté 38 mm versus TAXUS Express.
utcomes in SVs. At 9 months, the TAXUS Liberté
ong Lesion (B) studies. *After 9 months, the study populations were reduced
nt at baseline. QCA  quantitative coronary angiography.LAS L.25-mm stent exhibited significant reductions in in-
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703egment DS and late loss compared with the TAXUS
xpress stent. These differences became statistically nonsig-
ificant after propensity score adjustment although a clear
rend remained (Table 3). Both in-stent and in-segment
inary restenosis rates were significantly reduced with
AXUS Liberté but no longer met statistical significance
fter propensity score adjustment (Table 3). The TAXUS
iberté stent predominantly reduced focal in-stent resteno-
is, with no apparent edge effect (Tables 3 and 4).
Multivariate linear regression models demonstrated that
reatment with the TAXUS Liberté (vs. TAXUS Express) was
significant predictor of both lower DS (coefficient 6.11, p
0.0415) and less late loss (coefficient0.16, p 0.0171). In
ddition, a Cox regression model identified TAXUS Liberté as
significant predictor of reduced binary restenosis (odds ratio:
Table 2. Baseline Patient, Lesion, and Procedural Characteristics
TAXUS ATLAS Small V
TAXUS Express
(N  75)
TAXUS Libe
(N  261
Patient characteristics*
Male (%) 66.7 (50/75) 56.3 (147/261)
Age (yr) 64.7 9.4 (75) 63.4 11.1 (26
Previous CABG (%) 21.3 (16/75) 13.4 (35/261)
Previous MI (%) 32.0 (24/75) 28.7 (75/261)
Stable angina (%) 58.7 (44/75) 60.9 (159/261)
Unstable angina (%) 28.0 (21/75) 28.0 (73/261)
Smoking (%) 70.7 (53/75) 58.2 (152/261)
Diabetes (%) 44.0 (33/75) 36.4 (95/261)
Hyperlipidemia (%) 77.3 (58/75) 82.0 (214/261)
Hypertension (%) 81.3 (61/75) 76.6 (200/261)
Lesion characteristics by QCA*
Target vessel: LAD 36.5 (27/74) 41.0 (107/261)
Diameter stenosis (%) 69.97 10.59 (74) 67.26 10.91 (2
Lesion length (mm) 11.84 5.69 (72) 14.53 6.89 (26
Thrombus (%) 1.4 (1/74) 0.8 (2/261)
Calciﬁcation (%) 17.6 (13/74) 27.7 (72/260)
Modiﬁed ACC/AHA type B2/C (%) 58.1 (43/74) 69.0 (180/261)
Procedural characteristics
Clinical procedural success (%)‡ 96.0 (72/75) 96.6 (252/261)
Procedure time (min) 53.2 33.1 (75) 43.7 24.8 (25
No nontarget lesion treated 51.0 33.6 (58) 41.0 24.6 (19
Post-dilation (%) 36.0 (27/75) 40.6 (106/261)
Total stented length (mm) 19.2 4.3 (73) 22.1 8.6 (256
Stent:lesion length ratio§ 1.9 0.7 (70) 1.7 0.7 (255
Multiple stents implanted (%) 2.7 (2/75) 7.7 (20/261)
Use of GP IIb/IIIa inhibitor 41.3% (31/75) 21.1% (55/261)
*All baseline and lesion characteristicswere considered in the propensity score analysis andmultivar
the groups: previous percutaneous coronary intervention, heart failure, branch vessel disease, tota
30% with Thrombolysis In Myocardial Infarction flow grade 3, as visually assessed by the investiga
§Stent length data are nominal; lesion length data are from quantitative coronary angiography.
ACC/AHA American College of Cardiology/American Heart Association; CABG coronary arter
 quantitative coronary angiography..39, 95% CI: 0.18 to 0.83, p  0.0148) (Fig. 3). (At 12 months, patients receiving TAXUS Liberté 2.25
m had significantly greater freedom from target lesion
evascularization (TLR) compared with TAXUS Express
atients (Fig. 4). The TLR rate was statistically significantly
ower for TAXUS Liberté patients versus TAXUS Express
atients (6.1% vs. 16.9%, p  0.0039). After propensity
core adjustment, this difference was no longer statistically
ignificant, although a trend for reduced TLR remained
5.8% vs. 13.2%, p  0.08) (Table 5). Multivariate analysis
evealed that treatment with the TAXUS Liberté signifi-
antly reduced the risk of TLR versus the TAXUS Express
hazard ratio: 0.34, 95% CI: 0.16 to 0.72, p  0.0048) (Fig.
), consistent with the risk reduction observed for binary
estenosis.
AFETY OF TAXUS LIBERTÉ 2.25 MM IN SVS. In-hospital
TAXUS ATLAS Long Lesion
p Value
TAXUS Express
(N  145)
TAXUS Liberté
(N  150) p Value
0.11 68.3 (99/145) 73.3 (110/150) 0.34
0.36 62.3 12.0 (145) 63.3 10.2 (150) 0.45
0.09 11.0 (16/145) 10.0 (15/150) 0.77
0.58 39.3 (57/145) 36.0 (54/150) 0.56
0.73 53.8 (78/145) 66.7 (100/150) 0.0238
1.00 37.9 (55/145) 25.3 (38/150) 0.0199
0.05 62.8 (91/145) 71.3 (107/150) 0.12
0.23 29.0 (42/145) 28.0 (42/150) 0.85
0.37 71.7 (104/145) 85.3 (128/150) 0.0044
0.39 71.7 (104/145) 76.0 (114/150) 0.40
0.48 38.0 (54/142) 38.0 (57/150) 0.10
0.06 66.46 10.88 (142) 67.04 11.01 (150) 0.65
0.0025 21.64 7.28 (140) 28.08 8.31 (150) 0.0001
0.53† 5.6 (8/142) 0.7 (1/150) 0.0169†
0.08 29.6 (42/142) 48.0 (72/150) 0.0013
0.08 89.4 (127/142) 98.7 (148/150) 0.0008
0.73† 96.3 (79/82) 100.0 (150/150) 0.0431†
0.0074 52.4 24.0 (145) 52.6 32.4 (149) 0.96
0.0134 49.4 23.3 (114) 43.0 19.5 (103) 0.0313
0.47 58.6 (85/145) 53.3 (80/150) 0.36
0.0065 32.3 5.5 (142) 37.8 4.8 (150) 0.0001
0.0458 1.9 0.9 (140) 1.6 0.6 (150) 0.0001
0.18† 53.8 (78/145) 16.0 (24/150) 0.0001
0.0004 45.1% (65/144) 26.7% (40/150) 0.0010
lysis, alongwith the following variables, whichwere not statistically significantly different between
ion; †p values were calculated by Fisher exact test; ‡Defined as mean lesion diameter stenosis of
hout the occurrence of major adverse cardiac events as of the time of hospital discharge;
s graft; GP glycoprotein; LAD left anterior descending artery; MImyocardial infarction; QCAessel
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704s. 4.1%, p  0.38) were similar for the TAXUS Liberté
nd the TAXUS Express groups, respectively. The 12-
onth MACE rate was significantly lower for the TAXUS
iberté compared with that of the TAXUS Express, mainly
Figure 2. Primary End Point of In-Segment % Diameter Stenosis
Noninferiority testing results illustrate that the differences (Diff.) between
the groups, and upper 1-sided 95% conﬁdence interval (CI), whether unad-
justed or propensity score adjusted, were below the pre-speciﬁed noninfe-
riority margin for both the TAXUS ATLAS Small Vessel (A) and TAXUS
ATLAS Long Lesion (B) studies.
Table 3. Angiographic Outcomes at 9 Months: Per Protocol Population
Unadjusted
TAXUS ATLAS SV TAXUS Express TAXUS Libert
In-segment late loss (mm) 0.32 0.52 (54) 0.16 0.40 (207
In-segment diameter stenosis (%) 37.7 23.3 (54) 31.7 18.2 (207
In-segment binary restenosis (%) 31.5 (17/54) 17.9 (37/207)
In-stent restenosis (%) 25.9 (14/54) 13.0 (27/207)
Proximal edge restenosis (%) 2.2 (1/46) 4.5 (9/202)
Distal edge restenosis (%) 3.9 (2/51) 3.4 (7/205)
TAXUS ATLAS LL
Late loss (mm) 0.36 0.58 (91) 0.34 0.52 (126
Diameter stenosis (%) 32.6 19.3 (91) 31.7 17.2 (126
Binary restenosis (%) 18.7 (17/91) 14.3 (18/126)
Numbers shown are mean standard deviation (n) or % (count/sample size). *p values were calculAbbreviations as in Table 1.ttributable to the lower TLR rates (Table 5). Through 12
onths, there were no significant differences in overall or
ardiac mortality, MI, and stent thrombosis rates, either
nadjusted or adjusted (Table 5).
utcomes in LLs. In the TAXUS ATLAS LL study, all
-month angiographic outcomes, whether adjusted or un-
djusted, were comparable for TAXUS Liberté 38 mm and
AXUS Express (Table 3). Accordingly, the 12-month
LR rates were similar between the groups (Table 5).
AFETY OF TAXUS LIBERTÉ 38 MM IN LLS. MACE were
ignificantly reduced in the TAXUS Liberté patients
ompared with those in TAXUS Express patients both
n-hospital (0% vs. 4.1%, p  0.0134) and at 30 days (0%
s. 4.9%, p  0.0061). All 30-day MACE in TAXUS
xpress patients were exclusively MI. The 12-month
ACE rates were similar between the TAXUS Liberté
nd the TAXUS Express groups (Table 5), but freedom
rom MI through 12 months remained significantly
mproved for patients receiving TAXUS Liberté com-
ared with those receiving TAXUS Express. The MI
ate was significantly lower for TAXUS Liberté than
AXUS Express (1.4% vs. 6.5%, p  0.0246). Although
his difference at 12 months was no longer statistically
ignificant after propensity score adjustment, a trend
oward lower MI rate remained (1.7% vs. 5.1%, p  0.11)
Table 5). Multivariate analysis demonstrated that treat-
ent with TAXUS Liberté significantly reduced the risk
f MI by 81% versus treatment with TAXUS Express
Fig. 5).
To further characterize the reduced risk of MI, we
nalyzed patients with single and multiple stents separately;
he difference in MI rate was attributable to the single stent
ohort only (Fig. 6B). Moreover, the lower MI rate with
AXUS Liberté was predominantly due to a significant
eduction in the incidence of periprocedural (in-hospital)
Adjusted
p Value TAXUS Express TAXUS Liberté p Value
0.0146 0.33 0.16 0.08
0.0442 38.1 31.4 0.19
0.0279 34.9 17.1 0.06
0.0205 22.5 13.0 0.13
0.69* 1.3 4.2 0.11
1.00* 5.1 3.3 0.65
0.78 0.32 0.38 0.51
0.71 33.6 32.6 0.69
0.39 17.0 17.2 0.98
Fisher exact test.é
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705on–Q-wave MI with TAXUS Liberté versus TAXUS
xpress (Fig. 6C).
No stent thromboses were reported for TAXUS Liberté.
he 12-month cardiac mortality, adjusted or unadjusted,
as significantly lower for the TAXUS Liberté patients
han the control subjects. Multivariate analysis did not
emonstrate a significant risk reduction for cardiac death by
reatment with TAXUS Liberté (Fig. 5).
iscussion
he TAXUS ATLAS SV and LL trials were designed to
ssess the safety and efficacy of the second-generation
AXUS Liberté stent that uses identical polymer and
aclitaxel release but more uniform strut distribution and
hinner struts than the first-generation TAXUS Express
tent in challenging patients with SVs or LLs.
Figure 3. Multivariate Predictors of 9-Month Binary Restenosis and 1-Year
Table 4. In-Stent Restenosis Pattern and at 9 Month
TAXUS Expre
(N  75)
In-Stent Restenosis Pattern
I focal 18.5% (10/5
II diffuse 3.7% (2/54
III proliferative 1.9% (1/54
IV total occlusion 1.9% (1/54
Post-procedure measurement is an in-stent measurement. *p values w
SV small vessel; TIMI Thrombolysis In Myocardial Infarction.CI  conﬁdence interval; RVD  reference vessel diameter; SE  standard error; SVThe TAXUS ATLAS SV study demonstrated that the
AXUS Liberté 2.25-mm stent was noninferior versus the
AXUS Express in terms of 9-month in-segment DS, and
n addition, reduced binary restenosis at 9 months and the
eed for TLR at 1 year in subjects with SVs (2.5 mm).
ndeed, multivariate regression analysis confirmed that use
f TAXUS Liberté was an independent predictor of reduced
estenosis and TLR in SVs. In this regard, the TAXUS
iberté showed improved efficacy compared with that seen
ith the TAXUS Express.
The TAXUS ATLAS LL study demonstrated that the
ew TAXUS Liberté 38-mm stent was noninferior versus
he TAXUS Express in terms of 9-month in-segment DS.
mportantly, however, TAXUS Liberté reduced the rate of
I at 1 year due to a significant reduction in the rate of
eriprocedural MI in the single stent cohort. Multivariate
egression analysis showed that the TAXUS Liberté 38 mm
n the TAXUS ATLAS SV Study
he TAXUS ATLAS SV Study
TAXUS Liberté
(N  261) p Value
9.2% (19/206) 0.05
1.5% (3/206) 0.28*
1.5% (3/206) 1.00*
1.0% (2/206) 0.50*
culated by the Fisher exact test.TLR is for t
ss
4)
)
)
)
ere cal small vessel; TLR  target lesion revascularization.
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706as an independent factor for reducing the MI risk,
onfirming the improved safety profile of the TAXUS
iberté compared with that of the TAXUS Express in LLs
26 to 34 mm).
Taken together, these 2 studies demonstrate that the
hin-strut TAXUS Liberté stent may have specific clinical
enefits for patients with SVs or LLs, beyond simply
mproved deliverability. Given that the 2 stents use the same
Figure 4. Freedom From TLR Through 1 Year in the TAXUS ATLAS SV Stud
Abbreviations as in Figure 3.
Table 5. 12-Month Clinical Outcomes for the TAXUS ATLAS SV and LL Stud
Unadjusted
Clinical Outcome TAXUS Express TAXUS Liberté
TAXUS ATLAS SV (N  73) (N  254)
MACE (%) 26.8 (19/71) 13.4 (33/247)
Cardiac death (%) 4.2 (3/71) 1.2 (3/247)
MI (%) 4.2 (3/71) 2.4 (6/247)
Non–Q-wave MI (%) 2.8 (2/71) 1.6 (4/247)
TVR, overall (%) 22.5 (16/71) 10.5 (26/247)
TLR (%) 16.9 (12/71) 6.1 (15/247)
Stent thrombosis (%)† 1.5 (1/67) 0.4 (1/243)
Total death (%) 4.3 (3/69) 2.8 (7/249)
TAXUS ATLAS LL (N  145) (N  150)
MACE (%) 16.5 (23/139) 10.9 (16/147)
Cardiac death or MI (%) 9.4 (13/139) 1.4 (2/147)
Cardiac death (%) 3.6 (5/139) 0.0 (0/147)
MI (%) 6.5 (9/139) 1.4 (2/147)
Non–Q-wave MI (%) 5.0 (7/139) 1.4 (2/147)
TVR, overall (%) 10.1 (14/139) 10.2 (15/147)
TLR (%) 8.6 (12/139) 7.5 (11/147)
Stent thrombosis (%)† 0.7 (1/135) 0.0 (0/146)
Total death (%) 3.6 (5/139) 0.7 (1/147)
MACE: major adverse cardiac events; MImyocardial infarction; TLR target lesion revascularizatFisher exact test; †Rates of stent thrombosis per protocol definition and per Academic Research Consortiutent material, polymer coating, drug dose, and release
inetics, the observed clinical benefits are likely the result of
he more uniform strut pattern and thinner strut design.
Several previous studies have demonstrated that thinner-
trut stents are associated with a significant reduction of
linical and angiographic restenosis than thick-strut stents
9,10,14). Although the mechanism for this improved
utcome is not clearly understood, it may relate to reduced
Adjusted
p Value TAXUS Express TAXUS Liberté p Value
(N  73) (N  254)
0.0071 27.3 13.5 0.06
0.13* 2.1 1.4 0.61
0.42 9.2 2.5 0.26
0.62* 7.4 1.7 0.31
0.0084 19.3 10.3 0.07
0.0039 13.2 5.8 0.08
0.39* 0.8 0.4 0.64
0.46* 2.1% 2.7% 0.72
(N  145) (N  150)
0.1631 14.5 14.0 0.90
0.0024 7.6 1.7 0.0161
0.0261* 2.9 0.0 0.0317
0.0246 5.1 1.7 0.11
0.10* 4.1 1.7 0.24
0.97 9.4 13.1 0.37
0.72 8.0 10.4 0.54
0.48* 0.5 0.0 0.31
0.11* 2.9 0.4 0.07
R target vessel revascularization; other abbreviations as in Table 1. *p values were calculated byyies
ion; TVm (definite and probable) were identical.
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707eep vessel injury during implantation or improved healing
9). The relationship between stent strut thickness and
estenosis remains particularly evident in smaller vessels
9,10). A subanalysis of the ISAR-STEREO (Intracoronary
tenting and Angiographic Results: Strut Thickness Effect
n Restenosis Outcomes) trial indicated that the differences
etween thin- and thick-strut stents were only apparent in
atients with complex lesions (14). More recently, a ran-
omized trial of the sirolimus-eluting Cypher stent versus a
hin (0.0032 inch) strut bare-metal stent in a population at
edium risk of restenosis confirmed the efficacy of Cypher
n terms of reduced late loss and restenosis (15). However,
he absolute differences for late loss (0.40 mm) and angio-
raphic restenosis (13%) were much less between these 2
tents than the differences observed between Cypher and a
hick-strut (0.14 mm) bare-metal stent in the SIRIUS
Sirolimus-Eluting Stent in Coronary Lesions) trial (late
oss 0.57 mm; angiographic restenosis 27.4%) (1).
The TAXUS ATLAS trial is the first program to
ompare thick- and thin-strut paclitaxel-eluting stents.
he pivotal TAXUS ATLAS trial did not show any
ifferences in restenosis rates between TAXUS Liberté
nd TAXUS Express in workhorse lesions (12) and
eiterates the findings of lack of differences in outcomes
etween thin-strut and thick-strut bare-metal stents in
imple lesions in the ISAR-STEREO trial (14). Further-
ore, the TAXUS ATLAS LL study, excluding SVs
2.7 mm), failed to show any difference in clinical and
ngiographic restenosis between thin-strut and thick-
trut paclitaxel-eluting stents. Importantly, the restenosis
eduction with TAXUS Liberté versus TAXUS Express
n SVs is similar to the finding for thin- versus thick-strut
Figure 5. Multivariate Predictors of Cardiac Death, MI, and Cardiac Death
LL  long lesion; MI  myocardial infarction; other abbreviations as in Figureare-metal stents in the ISAR-STEREO trial. This wiffering outcome with thick and thin struts was ascribed
o less vessel injury during implantation of the thinner
truts in SVs (9), and a similar mechanism may be
esponsible for improved outcomes with TAXUS Liberté
ersus TAXUS Express in SVs. If so, this may explain
art of the benefit of the thinner-strut Xience V (Abbott
ascular, Santa Clara, California)/PROMUS (Boston
cientific Corporation) everolimus-eluting stent com-
ared with the thick-strut TAXUS Express in SVs of the
PIRIT III (Everolimus-Eluting Stent in Coronary Le-
ions) trial (16), although the differences in the active
rug and polymer must still be considered.
The TAXUS ATLAS LL study also highlights the
mportance of stent design in LLs (26 to 34 mm) that
ften require the placement of multiple stents. Compared
ith TAXUS Express, the new TAXUS Liberté 38-mm
tent decreased the frequency of multiple stent use in
hese LLs, and in addition significantly reduced the rate
f periprocedural MI. While multiple stenting with
ither the TAXUS Express or the Cypher stent (3
tents) can increase the rate of periprocedural MI versus
are-metal stent controls (4,17), the MI reduction in the
AXUS ATLAS LL study was predominantly observed
n the single stent cohorts and occurred despite the
reater 38-mm length of the TAXUS Liberté compared
ith the longest TAXUS Express stent (32 mm). This
enefit of TAXUS Liberté versus TAXUS Express seems
o be specific for LLs (26 to 34 mm), which were not
tudied in the previous TAXUS ATLAS workhorse trial
12). Given the identical drug/polymer coating for the 2
AXUS stents, this reduction in periprocedural MI seen
at 1-Year Follow-Up in the TAXUS ATLAS LL Studyor MIith the long TAXUS Liberté stent likely also results
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708rom the improved stent geometry (potentially less side
ranch “jailing”) and thinner struts (less deep plaque
njury and potential plaque embolization) than seen with
he thicker-strut TAXUS Express design in these longer
esions.
tudy limitations. Both the TAXUS ATLAS SV and LL
tudies are nonrandomized studies with historical con-
rol subjects drawn from the TAXUS IV and V trials.
he differences in baseline characteristics observed be-
ween TAXUS Liberté and TAXUS Express patients
ere compensated for by the use of propensity score
djustment. Multivariate analysis provided additional
ompensation.
Besides the evident differences in strut thickness, it is
Figure 6. MI in the TAXUS ATLAS LL Study
(A) Freedom from MI through 1 year. (B) MI rates at 12 months for patients re
stent cohorts; (C) In-hospital and out-of-hospital non–Q-wave MI for patients r
MI (all 5 creatine kinase-MB [CK-MB]) was similar for both stent groups, in-
pared with those seen in the TAXUS Liberté group. Notably, one-half of these
Abbreviation as in Figure 5.ossible that other differences in the mechanical and chysical properties (e.g., radial strength, gap size or open
reas between stent struts, and acute recoil) between
AXUS Liberté and TAXUS Express may have con-
ributed to the improved performance of TAXUS Lib-
rté. However, the designs of the TAXUS ATLAS SV
nd LL studies cannot distinguish the contributions of
hese individual factors on clinical and angiographic
utcomes.
Finally, intravascular imaging in the TAXUS ATLAS
V study might have provided additional insights to differ-
nces in vessel injury and response but was not included in
he protocol. Similarly, detailed side-branch analyses were
ot performed in the TAXUS ATLAS LL study to further
efine the specific mechanism of the reduction in peripro-
g TAXUS Liberté versus TAXUS Express in both single stent and multiple
g TAXUS Liberté versus TAXUS Express. While out-of-hospital non–Q-wave
al non–Q-wave MI rates were signiﬁcantly higher for TAXUS Express com-
-wave MIs were associated with CK-MB levels 5 upper limit of normal.ceivin
eceivin
hospit
non–Qedural MI in LLs.
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709onclusions
he new-generation paclitaxel-eluting TAXUS Liberté
tent, using a more uniform geometry and thinner struts,
ignificantly reduced the risk of restenosis in SVs and
eriprocedural MI in LLs compared with the earlier
AXUS Express platform. Since both stent platforms used
therwise identical drug/polymer coating, the improved
erformance and safety profile of the TAXUS Liberté is
ost likely the result of the thinner struts and improved
tent geometry.
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APPENDIX
or a list of the TAXUS ATLAS Small Vessel/Long Lesion Stent Study
rganization, please see the online version of this article.
